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z Evidence summary
An estimated 1.7 million people in the 
United States are living with limb loss. 
The number is expected to increase be-
cause of ongoing military conflicts.1 The 
incidence of PLP is 60% to 80% among 
amputees.1 
A multidisciplinary approach 
A lack of comparative clinical trials of 
therapies for PLP has led health-care 
providers to adopt a multidisciplinary 
approach that combines evaluative man-
agement, desensitization, psychotherapy, 
and pharmacotherapy (FIGURE). 
Evaluative management, based 
largely on expert opinion, includes as-
sessing the fit of the prosthesis, treating 
referred pain, and assessing aggravating 
factors. Because residual limb pain can 
exacerbate PLP, adjusting a poorly fit-
ting prosthesis or providing the patient 
with NSAIDs when there is evidence of 
stump inflammation may adequately 
control pain.2,3 Anatomically distant 
pain syndromes, such as hip or lower 
back pain, can also aggravate PLP and 
should be managed to provide optimal 
pain relief.2 
Desensitization, using TENS, has re-
duced PLP in multiple placebo-controlled 
trials and epidemiologic surveys.2-5 TENS 
is an easy-to-use, low-cost, noninvasive, 
first-line therapy.5 Its long-term effective-
ness in alleviating PLP remains unknown.2 
Some experts suggest that pain reductions 
after 1 year of treatment are comparable 
to placebo.2 Other forms of desensitiza-
tion (percussion and massage) are sup-
ported only by anecdotal reports.
Psychotherapy, including biofeed-
back, has been found in several case 
no	single	best	therapy	for	phantom	limb	
pain	(PlP)	exists.	Treatment	requires	a	
coordinated	application	of	conservative,	
pharmacologic,	and	adjuvant	therapies.	
	 evaluative	management	(including	
prosthesis	adjustment,	treatment	of	
referred	pain,	and	residual	limb	care)	
should	be	tried	initially	(strength	of	
recommendation	[sor]:	C,	expert	
opinion).	other	first-line	treatments	
such	as	transcutaneous	electrical	nerve	
stimulation	(Tens)	(sor:	A,	multiple	
high-quality	randomized,	control	trials	
[rcTs]),	and	biofeedback	(sor:	B,	
numerous	case	studies)	can	reduce	PlP.	
Pharmacotherapy,	including	opioids,	
anticonvulsants	(gabapentin),	and	
nonsteroidal	anti-inflammatory	drugs	
(nsaIDs),	can	also	relieve	pain	(sor:	B,	
initial	rcTs	and	inconsistent	findings).
	 adjuvant	therapies	(mirror	box	
therapy,	acupuncture,	calcitonin,	and		
n-methyl	d-aspartate	receptor	antagonists)	
haven’t	been	rigorously	investigated	for	
alleviating	PlP,	but	can	be	considered	for	
patients	who	have	failed	other	treatments.
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studies to effectively treat chronic 
PLP.2,5 Psychotherapy can reportedly 
reveal the underlying mechanisms 
(muscle spasm, vascular insufficiency) 
and therefore direct therapeutic inter-
ventions by biofeedback or other focus 
techniques.2 
Pharmacotherapy is best used as an ad-
junct to other treatments.2 Although PLP 
is typically treated as neuropathic pain, 
only a few medications have been criti-
cally evaluated for treating it.6 Morphine 
(number needed to treat [NNT]=2.5; 
95% confidence interval [CI], 1.9-3.4) 
and other opioids, including tramadol 
(NNT=3.9; 95% CI, 2.7-6.7 in neuro-
pathic pain) help some patients.6,7 Despite 
the proven benefit of tricyclic antidepres-
sants (TCAs) in other neuropathic pain 
conditions, a recent RCT demonstrated 
no benefit of TCAs over placebo in PLP.8 
Anticonvulsants, including gabapentin, 
have documented benefit in neuropathic 
pain modalities and are often used for 
Management of phantom limb pain1-10
figuRe
Adjuvant therapy
•	acupuncture†
•	Mirror	box	therapy†	
•	virtual	reality
•	calcitonin†
•	n-methyl-d-aspartate	
			receptor	antagonists
refer to specialist
•	Physical	medicine	and	rehabilitation
•	Pain	management
•	orthopedics
Consider referral for: 
•		socket	adjustment
•		residual	limb	injection
•		surgical	removal
if neuroma or ho  
is present
if no pain relief
Consider 
alternatives
if no pain relief
Evaluative management
•	Prosthesis	adjustment	(if	ill-fitting)*
•		referred	pain	management		
(eg,	lower	back,	bladder)*
•		specific	irritant	management		
(eg,	temperature,	diet)*
•		residual	limb	care	(eg,	neuroma,	ho,		
verrucous	hyperplasia,	folliculitis)*
Conservative management
•		Desensitization	techniques	(Tens,‡	percussion,*	
massage*)
•		referral	to	PT,	oT,	prothetist	for	dynamic		
evaluation	and	other	pain	management	methods		
(eg,	heat,	ultrasound)†
•		Biofeedback	and	underlying	mechanism	therapy†
Pharmacotherapy
(attempt	sequentially	or	in	combination)
•	nsaIDs,†	acetaminophen
•	Weak	opioids,‡	strong	opioids‡
•	anticonvulsant	(gabapentin,	pregabalin)‡
•		antidepressants*	(Tcas)	if	concomitant		
depression	or	other	psychological	disorders
ho,	heterotopic	ossification;	nsaIDs,	nonsteroidal	anti-inflammatory	drugs;	oT,	occupational	therapy;	PT,	physical	therapy;	Tcas,	tricyclic		
antidepressants;	Tens,	transcutaneous	electrical	nerve	stimulation.
*expert	opinion.
†case	studies.
‡randomized	controlled	trials	or	cohort	studies.
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PLP.6 However, their value in reducing 
PLP is still under investigation.6 One 
2002 RCT showed benefit regarding an 
improvement of the visual analog scale 
by an average of 3 points (on a 10-point 
scale) after 6 weeks of gabapentin ther-
apy.9 A similarly designed 2006 RCT of 
gabapentin, however did not identify sig-
nificant pain reductions.10 
Promising adjuvant therapies  
use mirroring techniques
Of the adjuvant treatments mentioned 
previously, only mirror box therapy has 
shown promise. This technique allows the 
amputee to perceive the missing limb by 
focusing on the reflection of the remain-
ing limb during specific movements and 
activities. Theoretically, this perception 
allows reconfiguration of the amputee’s 
sensory cortex. 
Virtual reality therapy employs simi-
lar techniques based on the idea that the 
brain can be deceived. Initial case studies 
are promising and have prompted fur-
ther research.11 
Recommendations
The US Department of Veterans Affairs 
and Department of Defense recently issued 
clinical guidelines for rehabilitating lower-
limb amputees that include a segment on 
pain management.12 The guidelines stress 
the importance of an interdisciplinary 
team approach that addresses each pa-
thology plaguing the amputee. 
They recommend narcotics during 
the immediate postoperative period, fol-
lowed by transition to a non-narcotic 
medical regimen during the rehabilitation 
process. The guidelines don’t support a 
single, specific pain control method over 
others; they recommend the following 
approaches to PLP: 
• pharmacologic treatment, which 
may include antiseizure medications, tri-
cyclic antidepressants, selective serotonin 
reuptake inhibitors, NSAIDs, dextro-
fast track
Of the available 
adjuvant  
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managing  
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Phantom limb pain management
•  Does routine amniotomy have a role in normal labor?
•   Does reducing smoking in the home protect children  
from the effects of second-hand smoke?
Get the answers to these Clinical Inquiries by going to www.jfponline.com 
and clicking on “Online Exclusives” in the left-hand navigation bar.
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methorathane, or long-acting narcotics
• epidural analgesia, patient- 
controlled analgesia, or regional analgesia
• nonpharmacologic therapies, in-
cluding TENS, desensitization, scar mo-
bilization, relaxation, and biofeedback. n
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The diagnosis and management of psychotic and mood disorders is an evolv-ing process and an important clinical topic for primary care clinicians (PCPs). 
Although many reports exist on the prevalence and treatment of depression in pri-
mary care, far less information is available about patients in this setting with depres-
sion accompanied by symptoms of mania or hypomania.1
To facilitate a dialogue on the identifi cation and treatment of psychotic and 
mood disorders, we invited 4 expert faculty members to present actual patient cases 
followed by a panel discussion in which the collective experience of all the faculty 
lends further practical insights into the nuances of management of such patients 
in both inpatient and outpatient settings. In particular, these cases underscore the 
importance of being alert to critical clues in a patient’s history or the family’s history. 
A larger version of this panel discussion appears in a supplement to the december 
2008 issue of CURRENT PSYCHIATRY. We’ve extracted the portion that we felt would be 
of most interest to primary care providers.
The case selected for presentation here is by david Muzina, Md, and concerns 
a 20-year-old man who was referred for psychiatric evaluation by his PCP and psy-
chologist for treatment of mood swings, anxiety, and confusion. He had been given 
sertraline and then venlafaxine, but discontinued both medications on his own. His 
symptoms began rather abruptly 14 months earlier, coinciding with an intense pro-
gram of weight lifting and supplement use to change his self-described smallness. 
Profound, persistent sadness and feeling “dead inside” were his chief complaints, 
and they had led to a break-up with his girlfriend, which distressed him greatly and 
preoccupied his thinking. He also believed his parents were hiding from him the 
truth of a signifi cant birth defect.
Following the case presentation is a faculty discussion of several pivotal issues 
in the management of mood disorders:
• Pitfalls to avoid during the diagnostic evaluation
• Pros and cons of monotherapy and combination therapy
•  Mechanisms of action of available medications and implications for an eff ec-
tive treatment plan
•  Suggestions for enabling patient compliance with prescribed regimens
We hope the insights you glean from this exchange of practical clinical issues 
will enhance and confi rm your own approach to diagnosing and treating patients 
with psychotic and mood disorders.
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leaRnInG oBJeCTIves
After reviewing this material, clinicians should be better able to: 
•  Achieve early and accurate diagnosis of patients with mood disorders
• Utilize available screening tools eff ectively
•  Understand the mechanisms of action, hepatic eff ects, and other 
metabolic eff ects of available agents and their potential impact on 
treatment
•  develop an eff ective treatment plan that includes monotherapy or 
combination therapy
•  Select the most appropriate agent(s) for short- and long-term treat-
ment to meet individual patient needs
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Psychiatrists, primary care physicians, and other health care profession-
als who treat patients with psychotic and mood disorders
CMe aCCReDITaTIon sTaTeMenT
The University of Cincinnati designates this educational activity for a 
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nati College of Medicine is accredited by the ACCME to provide continu-
ing medical education for physicians.
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decreasing the value of the presentation. All educational materials are 
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levels of evidence. 
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